1887
  1. Home
  2. Eurosurveillance
  3. Volume 23, Issue 9, 01/Mar/2018
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, −42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2018.23.9.18-00086
2018-03-01
2024-04-18
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2018.23.9.18-00086
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/23/9/eurosurv-23-9-1.html?itemId=/content/10.2807/1560-7917.ES.2018.23.9.18-00086&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination and antiviral use in Europe. Overview of vaccination recommendations and coverage rates in the EU Member States for the 2013-14 and 2014-15 influenza seasons. VENICE technical report [Internet]. Stockholm: ECDC; 2016. Available from: http://venice.cineca.org/Seasonal-influenza-vaccination-antiviral-use-europe.pdf
  2. Hakin B, Cosford P, Harvey F. The flu immunisation programme 2013/14– extension to children. London: Department of Health; 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/225360/Children_s_flu_letter_2013.pdf
  3. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Geneva: WHO; 2017. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2017_18_north/en/
  4. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Europe). Flu News Europe. Summary week 7/2018 (12-18 February 2018). Stockholm: ECDC, Copenhagen: WHO/Europe; 2018. Available from: http://flunewseurope.org/Archives
  5. I-MOVE+. Protocol for hospital-based test negative case control studies to measure seasonal influenza vaccine effectiveness against influenza laboratory confirmed SARI hospitalisation among the elderly across the European Union and European Economic Area Member States. Paris: EpiConcept; 2016. Available from: https://drive.google.com/file/d/0B54XpZN4SY65OGRSTHlvOVZTMFE/view
  6. European Centre for Disease Prevention and Control (ECDC). Protocol for case control studies to measure pandemic and seasonal vaccine effectiveness in the European Union and European Economic Area. Stockholm: ECDC; 2009. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0907_TED_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Case_Control_Studies.pdf
  7. Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data. Euro Surveill. 2015;20(28):21187.  https://doi.org/10.2807/1560-7917.ES2015.20.28.21187  PMID: 26212144 
  8. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill. 2016;21(38):30348.  https://doi.org/10.2807/1560-7917.ES.2016.21.38.30348  PMID: 27684603 
  9. Emborg HD, Krause TG, Nielsen L, Thomsen MK, Christiansen CB, Skov MN, et al. Influenza vaccine effectiveness in adults 65 years and older, Denmark, 2015/16 - a rapid epidemiological and virological assessment. Euro Surveill. 2016;21(14):30189.  https://doi.org/10.2807/1560-7917.ES.2016.21.14.30189  PMID: 27101732 
  10. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls. Int J Epidemiol. 1990;19(1):205-13.  https://doi.org/10.1093/ije/19.1.205  PMID: 2190942 
  11. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373-9.  https://doi.org/10.1016/S0895-4356(96)00236-3  PMID: 8970487 
  12. Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942-51.  https://doi.org/10.1016/S1473-3099(16)00129-8  PMID: 27061888 
  13. Kissling E, Valenciano M, Pozo F, Vilcu A-M, Reuss A, Rizzo C, et al. 2015/16 I-MOVE/I-MOVE+ multicentre case control study in Europe: moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage mismatched influenza B among children. Influenza Other Respir Viruses. 2017;2017. PMID: 29125681 
  14. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. Geneva: WHO; 2016. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/2016_17_north/en/
  15. Rondy M, Gherasim A, Casado I, Launay O, Rizzo C, Pitigoi D, et al. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. Euro Surveill. 2017;22(41):17-00645.  https://doi.org/10.2807/1560-7917.ES.2017.22.41.17-00645  PMID: 29043961 
  16. Sullivan SG, Chilver MB, Carville KS, Deng Y-M, Grant KA, Higgins G, et al. Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017. Euro Surveill. 2017;22(43):17-00707.  https://doi.org/10.2807/1560-7917.ES.2017.22.43.17-00707  PMID: 29090681 
  17. Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter A-L, Hickman R, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro Surveill. 2018;23(5):18-00035.  https://doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035  PMID: 29409570 
  18. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. Geneva: WHO; 2018. Available from: http://www.who.int/influenza/vaccines/virus/recommendations/201802_recommendation.pdf?ua=1
  19. Rondy M, El Omeiri N, Thompson MG, Levêque A, Moren A, Sullivan SG. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studies. J Infect. 2017;75(5):381-94.  https://doi.org/10.1016/j.jinf.2017.09.010  PMID: 28935236 
  20. Public Health England (PHE). Summary of data to support the choice of influenza vaccination for adults in primary care. London: PHE; 2018. Available from: https://www.gov.uk/government/publications/flu-vaccination-supporting-data-for-adult-vaccines/summary-of-data-to-support-the-choice-of-influenza-vaccination-for-adults-in-primary-care
  21. Flannery B, Chung JR, Belongia EA, McLean HQ, Gaglani M, Murthy K, et al. Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018. MMWR Morb Mortal Wkly Rep. 2018;67(6):180-5.  https://doi.org/10.15585/mmwr.mm6706a2  PMID: 29447141 
  22. Castilla J, Navascués A, Casado I, Pérez-García A, Aguinaga A, Ezpeleta G, et al. Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. Euro Surveill. 2018;23(7):18-00057.  https://doi.org/10.2807/1560-7917.ES.2018.23.7.18-00057  PMID: 29471624 
  23. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter A-L, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126-37.  https://doi.org/10.1093/infdis/jiu048  PMID: 24446529 
  24. Rondy M, Larrauri A, Casado I, Alfonsi V, Pitigoi D, Launay O, et al. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. Euro Surveill. 2017;22(30):30580.  https://doi.org/10.2807/1560-7917.ES.2017.22.30.30580  PMID: 28797322 
  25. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):153.  https://doi.org/10.1186/1741-7015-11-153  PMID: 23800265 
  26. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31(1):49-57.  https://doi.org/10.1016/j.vaccine.2012.10.084  PMID: 23142300 
  27. European Centre for Disease Prevention and Control (ECDC). Types of seasonal influenza vaccine. Stockholm: ECDC. [Accessed 28 Feb 2018]. Available from: https://ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/types-of-seasonal-influenza-vaccine
  28. Impfkommission S. (STIKO). Wissenschaftliche Begründung für die Empfehlung des quadrivalenten saisonalen Influenzaimpfstoffs. [Scientific reason for recommending the quadrivalent seasonal influenza vaccine]. Epidemiologisches Bulletin. 2018;2. German. Available from: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2018/Ausgaben/02_18.pdf?__blob=publicationFile
  29. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017;16(7):1-14.  https://doi.org/10.1080/14760584.2017.1334554  PMID: 28562111 
  30. Rondy M, Launay O, Castilla J, Costanzo S, Puig-Barberà J, Gefenaite G, et al. InNHOVE/I-MOVE+working group. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. Vaccine. 2017;35(34):4298-306.  https://doi.org/10.1016/j.vaccine.2017.06.088  PMID: 28709555 
  31. European Centre for Disease Prevention and Control (ECDC). Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza – review of recent systematic reviews and meta-analyses. Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Scientific-advice-neuraminidase-inhibitors-2017.pdf
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Marc+Rondy&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rondy Marc</a>, <a href="/search?value1=Esther+Kissling&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kissling Esther</a>, <a href="/search?value1=Hanne-Dorthe+Emborg&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Emborg Hanne-Dorthe</a>, <a href="/search?value1=Alin+Gherasim&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gherasim Alin</a>, <a href="/search?value1=Richard+Pebody&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pebody Richard</a>, <a href="/search?value1=Ramona+Trebbien&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Trebbien Ramona</a>, <a href="/search?value1=Francisco+Pozo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pozo Francisco</a>, <a href="/search?value1=Amparo+Larrauri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Larrauri Amparo</a>, <a href="/search?value1=Jim+McMenamin&option1=author&noRedirect=true" class="nonDisambigAuthorLink">McMenamin Jim</a>, <a href="/search?value1=Marta+Valenciano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Valenciano Marta</a>, <a href="/search?value1=I-MOVE%2FI-MOVE%2B+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">I-MOVE/I-MOVE+ group</a></span>. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. <a href="/content/ecdc">Euro Surveill.</a> 2018;23(9):pii=18-00086. <a href="https://doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 26 Feb 2018;&nbsp;&nbsp; <span class="generated">Accepted</span>: 01 Mar 2018 </span> </p>
/content/10.2807/1560-7917.ES.2018.23.9.18-00086
/content/10.2807/1560-7917.ES.2018.23.9.18-00086
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error